Tag:

prostate cancer

Latest Headlines

Latest Headlines

Ablatherm ultrasound prostate cancer treatment rebuffed by FDA panel

The FDA's Gastroenterology & Urology Devices panel came down firmly against EDAP's Ablatherm system for treating low-risk, localized prostate cancer. The panel voted 9-0 on the device's effectiveness, 5-3 against its safety (with one abstention) and said the risks outweigh the benefits by a vote of 8-0 (with one abstention).

French devicemaker faces FDA scrutiny for prostate cancer device

French devicemaker EDAP TMS SA is facing FDA scrutiny for its robotic device for prostate cancer, as regulators questioned the product's safety and efficacy in a new report. 

ASCO preview: What's the outlook for cancer vaccines?

The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.

A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi

As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.

MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal

MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.

CTC levels could provide a prostate cancer survival clue

New research supports the use of a circulating tumor cell blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer.

GE Healthcare prostate cancer imaging agent spurs the formation of a U.K. Dx startup

A U.K. diagnostics startup is off and running, backed by nearly $21.3 million in financing to support development of a PET imaging agent for recurrent prostate cancer licensed from GE Healthcare.

Exosome Diagnostics has $27M to become a 'pillar of personalized medicine' in 2014

Exosome Diagnostics announces this morning it has raised $27 million and will go to market in 2014 with its first fluid-based diagnostic test, a noninvasive urine sample designed to detect prostate cancer without a biopsy.

Myriad's new prostate cancer Dx study could help it win Medicare coverage in June

Myriad Genetics is celebrating promising results from a study demonstrating the clinical utility of its Prolaris prostate cancer molecular diagnostic test. The Utah company hopes to use the data to win Medicare reimbursement for the test by this June.

Myriad touts positive data for Dx that predicts prostate cancer recurrence

Myriad Genetics, long known for its predictive breast cancer tests, said recent clinical data backs up assertions that one of its new diagnostic assays can successfully determine which men will face a recurrence or spread of prostate cancer after radical surgery.